Jul 8, 2026 06:14PM
Feb 5, 2026 07:00AM
Feb 3, 2026 11:39AM
Jan 26, 2026 08:15AM
Jan 20, 2026 08:45AM
Dec 18, 2025 08:15AM
Dec 5, 2025 04:55PM Tharimmune (THAR) files for 176.93M share offering by selling stockholders
Nov 6, 2025 04:17PM
Nov 6, 2025 04:16PM
Nov 3, 2025 09:05AM
Nov 3, 2025 09:05AM
Nov 3, 2025 09:04AM
Aug 26, 2025 09:38AM
Aug 20, 2025 08:01AM Tharimmune reports simulation results for opioid exposure drug TH104
Aug 20, 2025 08:00AM
Aug 13, 2025 08:01AM
Aug 13, 2025 08:01AM
Aug 5, 2025 08:00AM
Aug 5, 2025 08:00AM
Aug 4, 2025 08:01AM
Aug 4, 2025 08:00AM Tharimmune Issues Comprehensive Corporate Update including Lead TH104 as Critical National Security Solution Against Weaponized Fentanyl and TH023 Poised to Revolutionize Oral Antibody Delivery
Jun 17, 2025 08:13AM
Jun 17, 2025 08:01AM
May 19, 2025 08:01AM
May 6, 2025 08:03AM
May 6, 2025 08:01AM
May 1, 2025 08:01AM
Apr 30, 2025 08:03AM Tharimmune (THAR) Appoints Clay Kahler and Gary Stetz to its Board
Apr 30, 2025 08:01AM
Apr 28, 2025 08:04AM
Apr 28, 2025 08:01AM
Apr 15, 2025 09:00AM
Apr 7, 2025 08:00AM
Mar 31, 2025 08:03AM
Mar 31, 2025 08:00AM Tharimmune Announces Positive FDA Feedback on NDA Path for TH104 for Prophylaxis of Respiratory and/or CNS Depression for Ultrapotent Opioid Exposure
Mar 24, 2025 08:00AM
Mar 4, 2025 07:03AM
Mar 4, 2025 07:00AM
Jan 27, 2025 08:30AM
Dec 19, 2024 04:18PM
Dec 16, 2024 08:04AM
Dec 16, 2024 08:00AM Tharimmune Announces Phase 2 Study Plan for TH104 in Patients With Moderate-to-Severe Pruritus Associated With Primary Biliary Cholangitis and Provides a Business Update
Dec 6, 2024 04:20PM
Dec 6, 2024 04:15PM
Dec 6, 2024 09:57AM
Nov 27, 2024 07:00AM
Nov 27, 2024 07:00AM
Nov 18, 2024 08:00AM
Nov 13, 2024 08:03AM Tharimmune (THAR) Granted EU Patent for Delivery of Optimized Molecularly Targeted Therapeutics
Nov 13, 2024 08:00AM

430,618 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All